We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZYKADIA (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ZYKADIA
Date registered
Evaluation commenced
Decision date
Approval time
209 working days (255)
Active ingredients
ceritinib
Registration type
EOI
Indication
ZYKADIA (capsules) is now also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.